Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, Pharmacokinetics and Antiviral Activity of IONIS-HBVRx in Treatment-Naïve Patients With Chronic HBV Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 to 70 years~* Chronic HBV infection ≥6 months (e.g., positive for serum HBsAg ≥ 6 months)~* Plasma HBV DNA ≥ 2 x 1000 IU/mL (HBV DNA adequately suppressed for exploratory nucleos(t)ide analogue experienced cohort)~* Serum HBsAg ≥ 50 IU/mL~* Exploratory nucleos(t)ide analogue experienced cohort only: currently taking and have been taking tenofovir or entecavir without changes in drug, dose level and/or frequency of administration for ≥ 12 months and expect to continue taking without change through to the end of their participation in this study~Exclusion Criteria:~* Current or prior receipt of anti-HBV nucleos(t)ide analogue therapy. Patients who have failed prior interferon treatment, greater than 6 months prior to Screening, may be evaluated for possible participation in the study (not applicable for exploratory nucleos(t)ide analogue experienced cohort)~* History of liver cirrhosis and/or evidence of cirrhosis as determined by any of the following:~  1. Liver biopsy (i.e., Metavir Score F4) within 2 years of Screening, or~ 2. Fibroscan \> 12 KPa, within 12 months of Screening, or~ 3. AST-to-Platelet Index (APRI) \> 2 and Fibrosure result \> 0.7 within 12 months of Screening For patients without a test for cirrhosis in the above timeframes, Fibroscan, or APRI and Fibrosure, may be performed during the screening period to rule out cirrhosis~* History of liver failure as evidenced by ascites, hepatic encephalopathy, and/or gastric or esophageal varices~* History of liver disease other than Hepatitis B~* Co-infection with hepatitis C virus (HCV), human immunodeficiency virus (HIV), or hepatitis D virus (HDV)~* BMI \> 35 kg/m2~* History of, or suspected presence of vasculitis~* Received solid organ or bone marrow transplant~* Currently taking, or took within 3 months of Screening, any immunosuppressing drugs (e.g., prednisone)~* Diagnosed hepatocellular carcinoma or suspected hepatocellular carcinoma as evidenced by screening alpha-fetoprotein ≥ 200 ng/mL. If the screening alpha-fetoprotein is ≥ 50 ng/mL and \< 200 ng/mL, the absence of liver mass must be documented by imaging within 6 months before randomization~* Clinically-significant abnormalities aside from chronic HBV infection in medical history (e.g., previous acute coronary syndrome within 6 months of Screening, major surgery within 3 months of Screening, uncontrolled diabetes) or physical examination~* History of bleeding diathesis or coagulopathy~* History of extrahepatic disorders possibly related to HBV immune complexes (e.g., glomerulonephritis, polyarteritis nodosa)~* History of excess alcohol consumption within 6 months of Screening~* History of drug abuse or dependence, or recreational use of drugs: within 3 months of Screening for soft drugs (such as marijuana) and within 1-year of Screening for hard drugs (such as cocaine, phencyclidine \[PCP\])

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- IONIS-HBVRx (Type: EXPERIMENTAL): Ascending multiple doses of IONIS-HBVRx by subcutaneous (SC) injection
- Placebo (Type: PLACEBO_COMPARATOR): Sterile Normal Saline (0.9% NaCl) calculated volume to match active comparator

Based on this trial design, predict the completion outcome and termination type (if applicable).